Search results
Results From The WOW.Com Content Network
Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. [5] It is generally recommended for use with other antiretroviral medications . [ 5 ]
The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped.
It contains lamivudine, nevirapine, and zidovudine. [2] It is either used by itself or along with other antiretrovirals . [ 2 ] It is a recommended treatment in those who are pregnant . [ 2 ]
Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] It contains lamivudine , nevirapine , and stavudine . [ 1 ] It is either used by itself or along with other antiretrovirals . [ 1 ]
Lamividine/zidovudine is categorized pregnancy category C in the United States, meaning there are potential risks to the baby during pregnancy, but potential benefits may outweigh the risks. [7] Data supports the safety of this combination during pregnancy and is often preferred over other fixed dose combinations during pregnancy.
If used during the first trimester of pregnancy harm to the baby may occur. [5] Efavirenz/emtricitabine/tenofovir was approved for medical use in the United States in 2006, [5] [8] and in the European Union in 2007. [6] It is on the World Health Organization's List of Essential Medicines. [9]
Premature babies with NAS tend to recover at a much faster rate than a full term baby would. [4] Both neonatal and maternal factors such as gestational age (length of pregnancy starting from the first day of the last mentrual period), maternal substance use, genetics, and gender play a role in the symptoms expressed by the neonate. [9]
In the US, etravirine is indicated for the treatment of HIV-1 infection in treatment-experienced patients aged two years of age and older. [1]In the EU, etravirine, in combination with a boosted protease inhibitor and other antiretrovirals, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced people aged six years of ...